This site is only for UK healthcare professionals and contains promotional information.

Prescribing Information can be found at the bottom of this page.

Up to 5 years of proven psoriasis control, reinforced by real-world experience1–4

5 reasons to prescribe
ILUMETRI® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.5
  • Ilumetri Overview

Discover your reason to prescribe ILUMETRI®

CONFIDENCE IN SUSTAINED EFFICACY
for up to 5 years1

IMPROVED QUALITY OF LIFE6

CONSISTENT, FAVOURABLE SAFETY PROFILE1

CONVENIENT DOSING SCHEDULE
with only 4 doses per year during maintenance and flexible dosing to adapt to patient needs5

MORE COST
EFFECTIVE

than other biologics,7* with flat pricing across doses8

*When assessed at Week 28, compared with other targeted treatments that are usually assessed between 12 weeks and 16 weeks (such as brodalumab, guselkumab, ixekizumab, infliximab and secukinumab).7

Meet the patients

Marc, 63

Has signs of
metabolic syndrome

Georgia, 29

Suffers with
moderate itch

Build your own patient

Short Description – Fabio vel iudice vincam, sunt in culpa qui officia. Plura mihi bona sunt, inclinet, amari petere vellent. Tityre, tu patulae recubans sub tegmine fagi dolor.

Excepteur sint obcaecat cupiditat non proident culpa. Lorem ipsum dolor sit amet, consectetur adipisici elit.

Resources

ILUMETRI® itch patient profile
Download additional information about the benefits of ILUMETRI® for patients with moderate itch
ILUMETRI® metabolic syndrome patient profile
Download additional information about the benefits of ILUMETRI® for patients with metabolic syndrome
German case report
An ILUMETRI® case report demonstrating results in the real world
References
  1. Thaçi D, et al. Br J Dermatol 2021. DOI: 10.1111/bjd.19866.
  2. Tsianakas A, et al. Interim analysis of the non-interventional study TILOT: effectiveness of tildrakizumab in long-term treatment of moderate to severe plaque psoriasis in routine practice. EADV Congress. 29–31 October 2020. Poster: P1336.
  3. Drerup K, et al. Real world data from a large prospective cohort study (KTC) using tildrakizumab in psoriasis. EADV Congress. 29–31 October 2020. Poster: P1294.
  4. Burlando M, et al. Drugs Context 2021;10:2021-2-6.
  5. ILUMETRI® Summary of Product Characteristics. Almirall.
  6. Reich K, et al. Lancet 2017;390:276–288.
  7. NICE. Tildrakizumab for treating moderate to severe plaque psoriasis. Available at: https://www.nice.org.uk/guidance/ta575.
  8. MIMS. ILUMETRI®. Available at: https://www.mims.co.uk/drugs/skin/psoriasis-seborrhoea-ichthyosis/ilumetri.

UK-ILU-2100104 November 2021

My Favorites